Concord Biotech
Market cap ₹11,738 Cr
- P/E
- 41.99
- Day range
- ₹545.90 – ₹566.30
- 52-week range
- ₹493.50 – ₹807.50
- Volume
- 5.70 L
- Open
- ₹546.80
- Prev close
- ₹554.80
Latest results · Q2 FY27(consolidated)Revenue ₹309 Cr+25.1%Profit ₹70 Cr+10.3%Margin 22.5%YoY vs the same quarter last year
No red flags in exchange filings: no rising pledge, promoter selling, surveillance or critical filing on record.
CONCORDBIO in NSE indices and F&O
Research profile
Composite 44 / 100Factor percentiles
Derived metrics
- Earn. yield
- 2.4%
- Graham no.
- ₹169.47
- vs Graham
- -69.8%
- ROE ÷ P/B
- 2.3%
- 12-1 mom.
- -7.0%
- Return / vol
- -0.52
- Magic Formula
- #380
- Piotroski
- 3/6
- FCF yield
- 1.5%
- PEG
- 4.07
Appears in 8 scans
Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.
Peer comparison
All 68 in Pharma| Company | M-cap | P/E | P/B | ROE | ROCE | OPM | D/E | Sales YoY |
|---|---|---|---|---|---|---|---|---|
| Sun PharmaSUNPHARMA | ₹4.49 L Cr | 40.95 | 5.03 | 14.8% | 21.0% | 29.0% | 0.04 | +11.9% |
| Divi's LaboratoriesDIVISLAB | ₹2.93 L Cr | 87.19 | 16.88 | 16.2% | 22.0% | 43.0% | 0.00 | +35.4% |
| Torrent PharmaTORNTPHARM | ₹1.75 L Cr | 77.88 | 9.67 | 26.8% | 15.0% | 33.0% | 0.77 | +50.8% |
| Apollo HospitalsAPOLLOHOSP | ₹1.27 L Cr | 56.40 | 11.55 | 22.6% | 17.0% | 16.0% | 0.77 | +23.0% |
| Laurus LabsLAURUSLABS | ₹1.25 L Cr | 93.72 | 19.82 | 18.2% | 18.0% | 34.0% | 0.43 | +33.5% |
| Zydus LifesciencesZYDUSLIFE | ₹1.20 L Cr | 28.72 | 4.32 | 20.1% | 21.0% | 24.0% | 0.50 | +29.2% |
| Dr. Reddy's LabsDRREDDY | ₹1.17 L Cr | 41.63 | 2.97 | 11.6% | 13.0% | 20.0% | 0.19 | -1.5% |
| Concord BiotechCONCORDBIO | ₹11,738 Cr | 41.99 | 5.99 | 13.5% | 17.0% | 34.0% | 0.00 | +25.1% |
| Sector median | ₹24,603 Cr | 43.68 | 5.46 | 15.1% | 17.0% | 24.0% | 0.17 | +22.7% |
Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.
Latest news
Updated 2h agoHeadlines about Concord Biotech from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.
Key metrics
- P/E (TTM)
- 41.2
- Price / Book
- 5.66
- ROE (FY26)
- 13.5%
- ROCE (latest year)
- 17%
- Dividend yield
- 0.67%
Moving averages (NSE)
- 20-day
- ₹617.19
- Price below
- 50-day
- ₹673.4
- Price below
- 200-day
- ₹631.34
- Price below
Charts & trends
From company filings. Amounts in ₹ crore.
Revenue, profit & margin - quarterly
₹ crore; a loss shows red. Operating margin below, same periods.
- Revenue
- Net profit
Operating margin
Who owns the company
% of equity by quarter, latest Nov 2026
- Promoter
- Public
- DII
- FII
Cash flows
Where cash came from and went, by fiscal year (₹ crore)
- Operating
- Investing
- Financing
- Free cash flow
Return on equity
Net profit over shareholders' equity, by fiscal year
Equity vs debt
Shareholders' equity against borrowings (₹ crore); the ratio below, same years.
- Equity
- Debt
Debt to equity
Dividends per share
₹ by fiscal year of the ex-date; the latest year runs to date. Not adjusted for the bonus of 4 Nov 2026: earlier bars are per pre-bonus share.
Financial statements
| Line item | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 241 | 319 | 216 | 310 | 244 | 430 | 204 | 247 | 278 | 326 | 257 | 309 |
| YoY Sales growth | — | — | — | — | — | — | -5 | -20 | — | -24 | — | — |
| Expenses | 135 | 187 | 135 | 176 | 146 | 241 | 143 | 159 | 179 | 208 | 175 | 205 |
| Operating Profit | 106 | 132 | 81 | 134 | 98 | 189 | 61 | 88 | 98 | 118 | 82 | 104 |
| OPM % | 44% | 41% | 38% | 43% | 40% | 44% | 30% | 36% | 35% | 36% | 32% | 34% |
| Other Income | 11 | 11 | 12 | 10 | 17 | 9 | 15 | 16 | 7 | 15 | 14 | 10 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 14 | 14 | 13 | 13 | 13 | 15 | 18 | 18 | 19 | 20 | 18 | 18 |
| Profit before tax | 103 | 129 | 80 | 130 | 101 | 184 | 59 | 86 | 86 | 114 | 78 | 95 |
| Tax % | 25% | 26% | 25% | 27% | 25% | 24% | 25% | 26% | 26% | 22% | 26% | 27% |
| Net Profit | 78 | 95 | 60 | 96 | 76 | 140 | 44 | 63 | 64 | 88 | 58 | 70 |
| EPS in Rs | ₹3.71 | ₹4.54 | ₹2.85 | ₹4.58 | ₹3.63 | ₹6.71 | ₹2.11 | ₹3.04 | ₹3.08 | ₹4.24 | ₹2.80 | ₹3.38 |
From company filings, updated 19 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.
Working-capital cycle
+54 days since Mar 2021
-18 days since Mar 2021
-1 days since Mar 2021
+37 days since Mar 2021
+53 days since Mar 2021
Strengths, risks & growth
Incorporated in 1984, Concord Biotech Limited is an India-based R&D-driven biopharma company and manufacturer of fermentation-based APIs across immunosuppressants and oncology. [1]
Strengths
- Company has reduced debt.
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 28.2%
Risks
- The company has delivered a poor sales growth of 11.3% over past five years.
- Company has high debtors of 159 days.
Compounded Sales Growth
- 10 Years
- —
- 5 Years
- +11%
- 3 Years
- +7%
- TTM
- +4%
Compounded Profit Growth
- 10 Years
- —
- 5 Years
- +1%
- 3 Years
- +1%
- TTM
- -12%
Stock Price CAGR
- 10 Years
- —
- 5 Years
- —
- 3 Years
- -3%
- 1 Year
- -23%
Return on Equity
- 10 Years
- —
- 5 Years
- +18%
- 3 Years
- +18%
- Last Year
- +13%
Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.
Shareholding pattern
| Holder | Mar 2026 | Jun 2026 | Sept 2026 | Nov 2026 | Change |
|---|---|---|---|---|---|
| Promoter | 44.08% | 44.08% | 44.09% | 44.09% | 0.00 pp |
| FII | 7.79% | 7.53% | 7.28% | 7.33% | +0.05 pp |
| DII | 9.22% | 9.37% | 10.95% | 11.02% | +0.07 pp |
| Public | 38.90% | 39.04% | 37.68% | 37.58% | -0.10 pp |
Filed with NSE for Nov 2026: promoters 44.09%, public 55.91%
Analysts & fund holdings
Who holds the shares, quarter by quarter
Mutual funds 5.85% (+0.01 pp)- Promoters44.1%
- Foreign institutions7.3%
- Mutual funds5.8%
- Insurance4.3%
- Other domestic institutions0.9%
- Retail6.5%
- Others31.0%
| Fund | % of company | % of fund | 3-month change |
|---|---|---|---|
| DSP Small Cap Fund | 2.68% | 1.61% | +0.68 pp |
| SBI Healthcare Opp Fund | 0.95% | 1.97% | +0.08 pp |
| DSP Healthcare Fund | 0.75% | 2.46% | +0.52 pp |
| Edelweiss Small Cap Fund | 0.58% | 1.05% | -0.13 pp |
| Altiva Equity Ex-Top 100 Long-Short Fund | 0.22% | 1.75% | -0.59 pp |
Scorecard
- Performance
- Low
- Valuation
- High
- Growth
- Low
- Profitability
- High
- Entry point
- Good
- Red flags
- Low
Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.
Risk & trend
From 292 daily sessions to 18 Nov 2026. Adjusted for 1 corporate action.
Risk
- Volatility (1Y)
- 42.3%
- Downside volatility
- 38.9%
- Worst 5% of days
- 4.1%
- Average of that tail
- 5.4%
- Max drawdown (1Y)
- 40.1%
- Below its peak
- 33.8%
Against the market
- Beta vs Nifty 50
- 0.90
- Correlation
- 0.29
- Relative strength (3M)
- -29.8%
- ATR (14)
- 5.4%
Return
- Return 1M
- -16.2%
- Return 3M
- -25.9%
- Return 6M
- -0.3%
- Return 1Y
- -22.0%
- vs 200-day average
- -11.1%
Momentum
- RSI (14)
- 36.5
- MACD histogram
- -4.59
- Stochastic %K
- 10.9
- ADX (14)
- 21.5
- +DI / −DI
- 18.5 / 33.5
- Money flow index
- 26.1
Participation
- Delivery (20d avg)
- 43.9%
- vs its 60-day baseline
- -2.2 pts
- Volume vs 20-day
- +1.0σ
- Close vs day's VWAP
- +0.2%
- 52-week position
- 16 / 100
These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.
Financial quality
From consolidated statements to 30 Sept 2026.
Piotroski F-Score
3 of 6 tested
- Return on assets positive — passed
- Operating cash flow positive — not testableno cash flow statement for this period
- Return on assets improving — failed
- Cash flow exceeds profit — not testableneeds cash flow and profit against assets
- Debt to assets falling — passed
- Current ratio improving — failed
- No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
- Operating margin improving — failed
- Asset turnover improving — passed
- Free cash flow
- ₹172 Cr
- FCF yield
- 1.5%
- Cash conversion
- 1.03
- Accruals ratio
- -0.003
- Net debt
- -₹6 Cr
- Net debt / equity
- -0.00
- EV / sales
- 10.02
- PEG
- 4.07
- Capex intensity
- 9.0%
- Revenue CAGR
- -19.7%
- Profit CAGR
- -37.3%
Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.
Corporate actions
- bonusNot available — not reported in this filing
Bonus 1:1
4 Nov 2026ex-date - dividend₹7.55
Dividend - Rs 7.55 Per Share
24 Jul 2026ex-date - dividend₹10.70
Dividend - Rs 10.70 Per Share
3 Sept 2025ex-date - dividend₹8.75
Dividend - Rs 8.75 Per Share
21 Jun 2024ex-date - otherNot available — not reported in this filing
Annual General Meeting
21 Jun 2024ex-date
Company announcements
Intimation of allotment of Bonus equity Shares
Transcript of Q2 - FY27 Earnings call held on October 28, 2026
Earning Call Recording- For the Second Quarter and half year ended on September 30, 2026
Intimation of Schedule of Analyst / Institutional Investor meetings under the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015 to be held on 03rd and 4th November, 2026.
Press release - For the Second quarter and half year ended on September 30, 2026
Investor's presentation on unaudited standalone and consolidated financial results for the second quarter and half year ended on September 30, 2026
The Board of Directors at its meeting held on October 27, 2026 has fixed Wednesday, November 04, 2026 as record date for issuance of Bonus equity shares in the ratio of 1:1.
Unaudited Standalone and Consolidated Financial Results for the second quarter and half year ended on September 30, 2026.
The Board of Directors of the Company, at its meeting held today i.e. Tuesday, October 27, 2026, has inter-alia considered and approved the Un-audited financial results for the quarter ....
Submission of Scrutinizer's report and Voting Results of Postal Ballot dated September 23, 2026
Earnings Call Invite for the operational and financial performance of the Company for the Quarter and half year ended on September 30, 2026
Concord Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/10/2026 ,inter alia, to consider and approve unaudited Standalone and Consolidated ....
In compliance with regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, we furnish herewith certificate received from RTA of the Company.
Pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time and as per the Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading ....
Newspaper advertisement for Notice of Postal Ballot dated September 23, 2026 and Remote E-Voting Information
Filed with BSE (scrip 543960); the last 45 days. Documents open at bseindia.com.
Documents
Annual reports
Earnings calls
- Nov 2026TranscriptSlidesRecording
- Aug 2026TranscriptSlidesRecording
- Jun 2026TranscriptSlidesRecording
- Feb 2026TranscriptSlides
- Nov 2025TranscriptSlides
- Aug 2025TranscriptSlides
Credit ratings
- Rating update · 23 Sep from icra
- Rating update · 23 Jul 2025 from icra
- Rating update · 9 May 2024 from icra
- Rating update · 10 Apr 2023 from icra
- Rating update · 7 Apr 2022 from icra
- Rating update · 4 Feb 2021 from icra
Documents open at BSE or the rating agency that issued them.
Sourced from the company's NSE XBRL filing dated 28 Oct 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.
Concord Biotech: common questions
Answered from the figures on this page.